Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
Abstract Background Galcanezumab of 300 mg monthly is the FDA approved preventive medication for cluster headache (CH) during the cluster period. Compared to the 120 mg galcanezumab syringe for the treatment of migraines, the 100 mg syringe for CH has globally not been as widely available. The aim o...
| 出版年: | The Journal of Headache and Pain |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
BMC
2022-10-01
|
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s10194-022-01505-w |